Industry Improving On LMIC Drug Access Plans But Tropical Disease R&D Lacking
Argues Access To Medicine Foundation
The non-profit Access To Medicine Foundation’s latest report shows big pharma is making progress on drug access plans as new non-exclusive voluntary licences help facilitate sustainable supply, but there is still not enough R&D for tropical diseases.
You may also be interested in...
The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.
The UK firm’s obe-cel has met the primary endpoint in a Phase II acute lymphocytic leukemia trial, triggering filing plans and a $150m public offering as observers commend the drug’s competitive safety profile.
Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.